These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17470710)

  • 1. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006.
    Laskey WK; Yancy CW; Maisel WH
    Circulation; 2007 May; 115(17):2352-7. PubMed ID: 17470710
    [No Abstract]   [Full Text] [Related]  

  • 2. Problems with drug-eluting coronary stents--the FDA perspective.
    Muni NI; Gross TP
    N Engl J Med; 2004 Oct; 351(16):1593-5. PubMed ID: 15483274
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-eluting coronary stents--promise and uncertainty.
    Curfman GD; Morrissey S; Jarcho JA; Drazen JM
    N Engl J Med; 2007 Mar; 356(10):1059-60. PubMed ID: 17296828
    [No Abstract]   [Full Text] [Related]  

  • 4. Debating the risks of drug-eluting stents.
    Shuchman M
    N Engl J Med; 2007 Jan; 356(4):325-8. PubMed ID: 17251527
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-eluting stents "deliver heartburn": how do we spell relief going forward?
    Krucoff MW; Boam A; Schultz DG
    Circulation; 2007 Jun; 115(23):2990-4. PubMed ID: 17473280
    [No Abstract]   [Full Text] [Related]  

  • 6. Unanswered questions--drug-eluting stents and the risk of late thrombosis.
    Maisel WH
    N Engl J Med; 2007 Mar; 356(10):981-4. PubMed ID: 17296826
    [No Abstract]   [Full Text] [Related]  

  • 7. Stent thrombosis redux--the FDA perspective.
    Farb A; Boam AB
    N Engl J Med; 2007 Mar; 356(10):984-7. PubMed ID: 17296827
    [No Abstract]   [Full Text] [Related]  

  • 8. Summary of the Food and Drug Administration's Circulatory System Devices Advisory Panel meeting December 7 and 8, 2006, Gaithersburg, MD.
    Coons KC
    Cardiovasc Revasc Med; 2007; 8(1):2-4. PubMed ID: 17293261
    [No Abstract]   [Full Text] [Related]  

  • 9. Stent thrombosis in randomized clinical trials of drug-eluting stents.
    Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
    N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis.
    Pinto Slottow TL; Waksman R
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):1064-74. PubMed ID: 17525967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous coronary intervention in perspective: drug-eluting stents as a model for regulatory review.
    Kandzari DE; Farb A; Boam AB
    Circ Cardiovasc Interv; 2009 Dec; 2(6):574-9. PubMed ID: 20031776
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-eluting stents is their future as bright as their past?
    Kastrati A; Schömig A
    J Am Coll Cardiol; 2007 Jul; 50(2):146-8. PubMed ID: 17616298
    [No Abstract]   [Full Text] [Related]  

  • 13. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force.
    Hodgson JM; Stone GW; Lincoff AM; Klein L; Walpole H; Bottner R; Weiner BH; Leon MB; Feldman T; Babb J; Dehmer GJ;
    Catheter Cardiovasc Interv; 2007 Feb; 69(3):327-33. PubMed ID: 17219373
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent.
    Torguson R; Waksman R
    Am J Cardiol; 2008 Dec; 102(12):1624-30. PubMed ID: 19064016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents: some bare facts.
    Eisenberg MJ
    Lancet; 2004 Oct 23-29; 364(9444):1466-7. PubMed ID: 15500872
    [No Abstract]   [Full Text] [Related]  

  • 16. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent.
    Pinto Slottow TL; Waksman R
    Circulation; 2008 Mar; 117(12):1603-8. PubMed ID: 18362244
    [No Abstract]   [Full Text] [Related]  

  • 17. Trading restenosis for thrombosis? New questions about drug-eluting stents.
    Shuchman M
    N Engl J Med; 2006 Nov; 355(19):1949-52. PubMed ID: 17093244
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of stents in the current era: long-term antiplatelet therapy and late-stent thrombosis.
    Buxton B
    ANZ J Surg; 2008; 78(1-2):2-5. PubMed ID: 18199197
    [No Abstract]   [Full Text] [Related]  

  • 19. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.
    McFadden EP; Stabile E; Regar E; Cheneau E; Ong AT; Kinnaird T; Suddath WO; Weissman NJ; Torguson R; Kent KM; Pichard AD; Satler LF; Waksman R; Serruys PW
    Lancet; 2004 Oct 23-29; 364(9444):1519-21. PubMed ID: 15500897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stents in interventional cardiology].
    Grinius V; Navickas R; Unikas R
    Medicina (Kaunas); 2007; 43(3):183-9. PubMed ID: 17413246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.